426 related articles for article (PubMed ID: 22237175)
1. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
[TBL] [Abstract][Full Text] [Related]
2. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
[TBL] [Abstract][Full Text] [Related]
3. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
Nakamura R; La Rosa C; Longmate J; Drake J; Slape C; Zhou Q; Lampa MG; O'Donnell M; Cai JL; Farol L; Salhotra A; Snyder DS; Aldoss I; Forman SJ; Miller JS; Zaia JA; Diamond DJ
Lancet Haematol; 2016 Feb; 3(2):e87-98. PubMed ID: 26853648
[TBL] [Abstract][Full Text] [Related]
4. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.
Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O'Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK
Lancet; 2011 Apr; 377(9773):1256-63. PubMed ID: 21481708
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Russo D; Schmitt M; Pilorge S; Stelljes M; Kawakita T; Teal VL; Haber B; Bopp C; Dadwal SS; Badshah C
Lancet Haematol; 2024 Feb; 11(2):e127-e135. PubMed ID: 38142695
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
11. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial.
Aldoss I; La Rosa C; Baden LR; Longmate J; Ariza-Heredia EJ; Rida WN; Lingaraju CR; Zhou Q; Martinez J; Kaltcheva T; Dagis A; Hardwick N; Issa NC; Farol L; Nademanee A; Al Malki MM; Forman S; Nakamura R; Diamond DJ;
Ann Intern Med; 2020 Mar; 172(5):306-316. PubMed ID: 32040960
[TBL] [Abstract][Full Text] [Related]
12. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W
Lancet; 2015 Jun; 385(9984):2272-9. PubMed ID: 25817373
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Das R; Blázquez-Gamero D; Bernstein DI; Gantt S; Bautista O; Beck K; Conlon A; Rosenbloom DIS; Wang D; Ritter M; Arnold B; Annunziato P; Russell KL;
Lancet Infect Dis; 2023 Dec; 23(12):1383-1394. PubMed ID: 37660711
[TBL] [Abstract][Full Text] [Related]
16. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
18. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
19. Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.
Mori T; Kanda Y; Takenaka K; Okamoto S; Kato J; Kanda J; Yoshimoto G; Gondo H; Doi S; Inaba M; Kodera Y
Int J Hematol; 2017 Feb; 105(2):206-212. PubMed ID: 27796740
[TBL] [Abstract][Full Text] [Related]
20. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
